Comprehensive approach to advanced primary and recurrent ovarian cancer: A personal experience

Expert Review of Anticancer Therapy

Volumn 4, Issue 3, 2004, Pages 477-487

  Carmignani, C Pablo ^a   Sugarbaker, Paul H ^a  

^a WASHINGTON CANCER INSTITUTE   (United States)

Author keywords

Carcinomatosis; Cytoreductive surgery; Intraperitoneal chemotherapy; Ovarian cancer

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CYTOTOXIC AGENT; DOCETAXEL; DOXORUBICIN; DRUG CARRIER; GEMCITABINE; HETASTARCH; MITOXANTRONE; OXALIPLATIN; PACLITAXEL;

ABDOMINAL SURGERY; AREA UNDER THE CURVE; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CARDIOTOXICITY; CHOLECYSTECTOMY; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG METABOLISM; DRUG PENETRATION; DRUG SOLUTION; DRUG TRANSPORT; EPITHELIUM; ERADICATION THERAPY; GYNECOLOGIC CANCER; HEAT TREATMENT; HEMIDIAPHRAGM; HUMAN; INTESTINE RESECTION; MORBIDITY; NEPHROTOXICITY; NEUROTOXICITY; OCCUPATIONAL HAZARD; OCCUPATIONAL SAFETY; OMENTUM; OVARY CANCER; PELVIS SURGERY; PERIOPERATIVE PERIOD; PERITONEUM CANCER; POSTOPERATIVE CARE; PROGNOSIS; RECURRENT CANCER; REVIEW; SCORING SYSTEM; SURGICAL APPROACH; SURGICAL TECHNIQUE; TREATMENT CONTRAINDICATION; TREATMENT INDICATION;

EID: 2942612434     PISSN: 14737140     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737140.4.3.477     Document Type: Review

References (47)

1. Sampson J. Implantation peritoneal carcinomatosis of ovarian origin. J. Pathol. 2, 423-443 (1931).
2. Engel J, Eckel R, Schubert-Fritschle G et al. Moderate progress for ovarian cancer in the last 20 years: prolongation of survival but no improvement in the cure rate. Eur. J. Cancer 38, 2435-2445 (2002).
3. Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of 25 major cancers in 1990. Int. J. Cancer 80, 827-841 (1999).
4. Cramer D. Epidemiology and biostatistics. In: Practical Gynecologic Oncology, 3rd edition. Berek J, Hacker N (Eds), Williams and Wilkins, MD, USA (2000).
5. Delgado G, Chun B, Caglar H, Bepko F. Paraaortic lymphadenectomy in gynecologic malignancies confined to the pelvis. Obstet. Gynecol. 50, 418-423 (1977).
6. Young R, Perez C, Hoskins W. Cancer of the ovary. In: Cancer: Principles and Practice of Oncology, 4th edition, volume 1. De Vita V, Hellman S, Rosenberg S (Eds), JB Lippincott, PA, USA, 1226 (1993).
7. Hoskins WJ, McGuire WP, Brady MF et al. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am. J. Obstet. Gynecol. 170, 974-979 (1994).
8. Sugarbaker TA, Chang D, Koslowe P, Sugarbaker PH. Pathobiology of peritoneal carcinomatosis from ovarian malignancy. Cancer Treat. Res. 81, 63-74 (1996).
9. Esquivel J, Farinetti A, Sugarbaker PH. [Elective surgery in recurrent colon cancer with peritoneal seeding: when to and when not to proceed]. G. Chir. 20, 81-86 (1999).
10. Sugarbaker PH. Laser-mode electrosurgery. In: Peritoneal Carcinomatosis. Principles of Management. Sugarbaker PH (Ed.), Kluwer Academic Publishers, MA, USA, 375-385 (1996).
11. Zoetmulder FA, Sugarbaker PH. Patterns of failure following treatment of pseudomyxoma peritonei of appendiceal origin. Eur. J. Cancer 32A, 1727-1733 (1996).
12. Carmignani CP, Sugarbaker TA, Bromley CM, Sugarbaker PH. Intraperitoneal cancer dissemination: mechanisms of the patterns of spread. Cancer Metastasis Rev. 22, 465-472 (2003).
13. Vazquez Vde L, Sugarbaker PH. Total anterior parietal peritonectomy. J. Surg. Oncol. 83, 261-263 (2003).
14. Sugarbaker PH. Complete parietal and visceral peritonectomy of the pelvis for advanced primary and recurrent ovarian cancer. Cancer Treat. Res. 81, 75-87 (1996).
15. Sugarbaker PH. Peritonectomy procedures. Ann. Surg. 221, 29-42 (1995).
16. Sugarbaker PH. The subpyloric space: an important surgical and radiologic feature in pseudomyxoma peritonei. Eur. J. Surg. Oncol. 28, 443-446 (2002).
17. Vazquez Vde L, Sugarbaker PH . Cholecystectomy, lesser omentectomy and stripping of the omental bursa: a peritonectomy procedure. J. Surg. Oncol. 84, 45-49 (2003).
18. Zang RY, Zhang ZY, Li ZT et al. Impact of secondary cytoreductive surgery on survival of patients with advanced epithelial ovarian cancer. Eur. J. Surg. Oncol. 26, 798-804 (2000).
19. Los G, Mutsaers PH, van der Vijgh WJ, Baldew GS, de Graaf PW, McVie JG. Direct diffusion of cisdiamminedichloroplatinum(II) in intraperitoneal rat tumors after intraperitoneal chemotherapy: a comparison with systemic chemotherapy. Cancer Res. 49, 3380-3384 (1989).
20. Urano M, Kuroda M, Nishimura Y. For the clinical application of thermochemotherapy given at mild temperatures. Int. J. Hyperthermia 15, 79-107 (1999).
21. Ceelen WP, Hesse U, de Hemptinne B, Pattyn P. Hyperthermic intraperitoneal chemoperfusion in the treatment of locally advanced intra-abdominal cancer. Br. J. Surg. 87, 1006-1015 (2000).
22. Dedrick RL, Myers CE, Bungay PM, DeVita VT Jr. Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat. Rep. 62, 1-11 (1978).
23. van der Vange N, van Goethem AR, Zoetmulder FA et al. Extensive cytoreductive surgery combined with intra-operative intraperitoneal perfusion with cisplatin under hyperthermic conditions (OVHIPEC) in patients with recurrent ovarian cancer: a feasibility pilot. Eur. J. Surg. Oncol. 26, 663-668 (2000).
24. Steller MA, Egorin MJ, Trimble EL et al. A pilot Phase I trial of continuous hyperthermic peritoneal perfusion with high-dose carboplatin as primary treatment of patients with small-volume residual ovarian cancer. Cancer Chemother. Pharmacol. 43, 106-114 (1999).
25. Nicoletto MO, Padrini R, Galeotti F et al. Pharmacokinetics of intraperitoneal hyperthermic perfusion with mitoxantrone in ovarian cancer. Cancer Chemother. Pharmacol. 45, 457-462 (2000).
26. Deraco M, Rossi CF, Pennacchioli E et al. Cytoreductive surgery followed by intraperitoneal hyperthermic perfusion in the treatment of recurrent epithelial ovarian cancer: a Phase II clinical study. Tumori 87, 120-126 (2001).
27. de Bree E, Romanos J, Michalakis J et al. Intraoperative hyperthermic intraperitoneal chemotherapy with docetaxel as second-line treatment for peritoneal carcinomatosis of gynaecological origin. Anticancer Res. 23, 3019-3027 (2003).
28. de Bree E, Rosing H, Beijnen JH et al. Pharmacokinetic study of docetaxel in intraoperative hyperthermic intraperitoneal chemotherapy for ovarian cancer. Anticancer Drugs 14, 103-110 (2003).
29. Ozols RF, Young RC, Speyer JL et al. Phase I and pharmacological studies of adriamycin administered intraperitoneally to patients with ovarian cancer. Cancer Res. 42, 4265-4269 (1982).
30. Sugarbaker PH. Early postoperative intraperitoneal adriamycin as an adjuvant treatment for visceral and retroperitoneal sarcoma. In: Peritoneal Carcinomatosis: Drugs and Diseases. Sugarbaker PH (Ed.), Kluwer Academic Publishers, MA, USA, 15-30 (1996).
31. Ozols RF, Locker GY, Doroshow JH, Grotzinger KR, Myers CE, Young RC. Pharmacokinetics of adriamycin and tissue penetration in murine ovarian cancer. Cancer Res. 39, 3209-3214 (1979).
32. Los G, Sminia P, Wondergem J et al. Optimisation of intraperitoneal cisplatin therapy with regional hyperthermia in rats. Eur. J. Cancer 27, 472-477 (1991).
33. Panteix G, Beaujard A, Garbit F et al. Population pharmacokinetics of cisplatin in patients with advanced ovarian cancer during intraperitoneal hyperthermia chemotherapy. Anticancer Res. 22, 1329-1336 (2002).
34. Link KH, Roitman M, Holtappels M et al. Intraperitoneal chemotherapy with mitoxantrone in malignant ascites. Surg. Oncol. Clin. N. Am. 12, 865-872 (2003).
35. Mohamed F, Sugarbaker PH. Carrier solutions for intraperitoneal chemotherapy. Surg. Oncol. Clin. N. Am. 12, 813-824 (2003).
36. Sugarbaker PH, Averbach AM, Jacquet P, Stephens AD, Stuart OA. A simplified approach to hyperthermic intraoperative intraperitoneal chemotherapy (HIIC) using a self retaining retractor. Cancer Treat. Res. 82, 415-421 (1996).
37. Elias D, Antoun S, Goharin A, Otmany AE, Puizillout JM, Lasser P. Research on the best chemohyperthermia technique of treatment of peritoneal carcinomatosis after complete resection. Int. J. Surg. Investig. 1, 431-439 (2000).
38. Stuart OA, Stephens AD, Welch L, Sugarbaker PH. Safety monitoring of the coliseum technique for heated intraoperative intraperitoneal chemotherapy with mitomycin C. Ann. Surg. Oncol. 9, 186-191 (2002).
39. White SK, Stephens AD, Sugarbaker PH. Hyperthermic intraoperative intraperitoneal chemotherapy safety considerations. AORN J. 63, 716-724 (1996).
40. Piccart MJ, Bertelsen K, James K et al. Randomized intergroup trial of cisplatin/paclitaxel versus cisplatin/cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J. Natl Cancer Inst. 92, 699-708 (2000).
41. Mohamed F, Marchettini P, Stuart OA, Sugarbaker PH. Pharmacokinetics and tissue distribution of intraperitoneal paclitaxel with different carrier solutions. Cancer Chemother. Pharmacol. 52, 405-410 (2003).
42. Stephens AD, Alderman R, Chang D et al. Morbidity and mortality analysis of 200 treatments with cytoreductive surgery and hyperthermic intraoperative intraperitoneal chemotherapy using the coliseum technique. Ann. Surg. Oncol. 6, 790-796 (1999).
43. Look M, Chang D, Sugarbaker PH. Long-term results of cytoreductive surgery for advanced and recurrent epithelial ovarian cancers and papillary serous carcinoma of the peritoneum. Int. J. Gynecol. Cancer 13, 764-770 (2003).
44. Alberts DS, Liu PY, Hannigan EV et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N. Engl. J. Med. 335, 1950-1955 (1996).
45. Markman M, Bundy BN, Alberts DS et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group and Eastern Co-operative Oncology Group. J. Clin. Oncol. 19, 1001-1007 (2001).
46. Tentes AA, Tripsiannis G, Markakidis SK et al. Peritoneal cancer index: a prognostic indicator of survival in advanced ovarian cancer. Eur. J. Surg. Oncol. 29, 69-73 (2003).
47. Witkamp AJ, de Bree F, Kaag MM et al. Extensive cytoreductive surgery followed by intra-operative hyperthermic intraperitoneal chemotherapy with mitomycin-C in patients with peritoneal carcinomatosis of colorectal origin. Eur. J. Cancer 37, 979-984 (2001).